inmagene-biopharmaceuticals-secures-21-million-in-series-b-funding

By Akshay Kedari  Date: 2020-11-09

inmagene-biopharmaceuticals-secures-21-million-in-series-b-funding

Inmagene Biopharmaceuticals, a Chinese pharmaceutical company, has recently revealed that it has logged US$21 million from its Series B funding round which was led by Vertex Ventures China. Reportedly, the funding saw co-investment from investors like Kunlun Capital, Panacea Venture, and SCVC.

As per sources, the capital will be utilized for research and development, product in-licensing activities and global clinical trials. As of this date, Inmagene has managed to raise more than $40 million from fundraising. The company is a prominent drug developer that specializes in immunology-related therapeutic regions.

Inmagene’s management team is deeply rooted in China and has a strong global experience. Its pipeline is strengthened by two prospects- the first being its in-licenses clinical-stage foreign therapeutics that suits China, while the second being its strategic relations with global players along with whom it conducts wide-scale multi-center clinical trials.

It is worth noting that Inmagene leverages China's cost-efficient resources to create best-in-class drugs at an affordable price point. Moreover, it has commenced four new innovative programs for validated drug targets.

Speaking on the move, Dr. Jonathan Wang, CEO and Chairman, Inmagene, said that the company is grateful to Panacea, Vertex, SCVC and Kunlun along with other investors for providing strong support. This financing will help the firm strengthen its leading position in China’s immunology drug development space.

Mr. Tay Choon Chong, Managing Partner, Vertex Ventures China, commented that the organization is delighted to be a part of Inmagene's Series B funding round as its lead investor. The development of immunology-related therapeutics still remains as a 'blue ocean' in China.

Mr. Chong added that Inmagene has made some early breakthroughs in the field of immunology and has managed to develop a strong R&D pipeline. Vertex believes that with a broad global vision and robust innovative capabilities, Inmagene has the potential to develop more competitive products at a global scale to satisfy patients' needs.

Source Credit: https://www.pharmiweb.com/press-release/2020-11-09/inmagene-biopharmaceuticals-closed-21-million-series-b-financing-making-the-total-raised-to-date-o

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Tiger Global looking to raise USD 10 billion to create new venture fund

Tiger Global looking to raise USD 10 billion to create new venture fund

By Akshay Kedari

American investment firm Tiger Global is reportedly looking to create a capital fund for startups by securing USD 10 billion from investors. So far, the company has participated in over 100 investment rounds since the past three months and has manage...

Urban Company secures USD 190 million in funding round led by Prosus

Urban Company secures USD 190 million in funding round led by Prosus

By Akshay Kedari

Urban Company, an Indian gig marketplace that provides home maintenance services, has secured USD 190 million in a funding round which was led by Prosus N.V. Other participants in the fundraising included companies such as Steadview Capital, Tiger Gl...

Samsung might launch a foldable Android tablet in first quarter of 2022

Samsung might launch a foldable Android tablet in first quarter of 2022

By Akshay Kedari

After introducing three foldable smartphones in the past couple of years, South Korean multinational conglomerate Samsung Electronics is reportedly working on its first tri-folding Android tablet. According to reliable sources, the new product is lik...

Remote hiring startup Deel secures USD 156 million in Series C funding

Remote hiring startup Deel secures USD 156 million in Series C funding

By Akshay Kedari

Deel, a company that specializes in offering recruitment, payroll, and compliance tools, has reportedly secured USD 156 million during a Series C funding round which was led by YC Continuity Fund. The California-based startup has now reached a valuat...

Audi unveils the A6 e-Tron concept with 700 km range and 800 Nm torque

Audi unveils the A6 e-Tron concept with 700 km range and 800 Nm torque

By Akshay Kedari

Audi AG, a German multinational auto manufacturer of luxury vehicles has unveiled the A6 e-Tron concept which is soon likely to be made available globally. The production version which is expected to have a range of 700 km (more than 400 miles) is to...